September 1, 2016 05:32 PM EDT
R&D

Mo­men­ta’s failed pan­cre­at­ic can­cer drug is giv­en a mid­night fu­ner­al

Arsalan Arif

Founder

Pan­cre­at­ic can­cer has claimed an­oth­er biotech vic­tim. The tough on­col­o­gy tar­get proved re­sis­tant to Mo­men­ta Phar­ma­ceu­ti­cals’ necu­paranib at the halfway point in their Phase II …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times